2019
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal
Toma W, Kyte SL, Bagdas D, Jackson A, Meade JA, Rahman F, Chen ZJ, Del Fabbro E, Cantwell L, Kulkarni A, Thakur GA, Papke RL, Bigbee JW, Gewirtz DA, Damaj MI. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Experimental Neurology 2019, 320: 113010. PMID: 31299179, PMCID: PMC6708482, DOI: 10.1016/j.expneurol.2019.113010.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNicotine rewardPaclitaxel treatmentRewarding effectsTreatment of CIPNPaclitaxel-induced mechanical hypersensitivityTumor-bearing NSG micePaclitaxel-induced peripheral neuropathyNon-small cell lung cancer cell linesCell lung cancer cell linesA549 non-small cell lung cancer cell lineMecamylamine-precipitated withdrawalAntitumor activityIntraepidermal nerve fibersLung cancer cell linesLung tumor growthNSCLC cell viabilityTumor-bearing miceIntrinsic rewarding effectsPlace preference testCancer cell linesConditioned place preference testMechanical hypersensitivityAgonist R
2018
Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy
Curry Z, Wilkerson J, Bagdas D, Kyte S, Patel N, Donvito G, Mustafa M, Poklis J, Niphakis M, Hsu K, Cravatt B, Gewirtz D, Damaj M, Lichtman A. Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy. Journal Of Pharmacology And Experimental Therapeutics 2018, 366: jpet.117.245704. PMID: 29540562, PMCID: PMC6038031, DOI: 10.1124/jpet.117.245704.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisBenzodioxolesBiomarkersCarbamatesCell Line, TumorCell ProliferationChemokine CCL2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHumansHyperalgesiaInflammationMaleMiceMonoacylglycerol LipasesNociceptionP38 Mitogen-Activated Protein KinasesPaclitaxelPhosphoproteinsPiperidinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2SuccinimidesConceptsAntinociceptive effectPaclitaxel-induced mechanical allodyniaPaclitaxel-induced neuropathic painH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsMonoacylglycerol lipaseMonocyte chemoattractant protein-1Chemotherapy-induced neuropathyPaclitaxel-induced allodyniaPain side effectsPrimary hydrolytic enzymesCell lung cancer cellsSpinal dorsal hornDorsal root gangliaChemoattractant protein-1Novel pharmacologic strategiesPaclitaxel-treated animalsNumerous rodent modelsLung cancer cellsPlace preference paradigmMonoacylglycerol lipase inhibitorsIntrinsic rewarding effectsPhospho-p38 MAPKMechanical allodyniaNeuropathic pain